The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9272996 B1

Date of Patent:

Mar. 01, 2016

Filed:

Aug. 27, 2012

2-acylaminopropoanol-type glucosylceramide synthase inhibitors

Applicants:

Craig Siegel, Woburn, MA (US);

Cecilia M. Bastos, South Grafton, MA (US);

David J. Harris, Lexington, MA (US);

Angeles Dios, Ashland, MA (US);

Edward Lee, Sudbury, MA (US);

Richard Silva, Needham, MA (US);

Lisa M. Cuff, Leominster, MA (US);

Mikaela Levine, Swampscott, MA (US);

Cassandra A. Celatka, Hull, MA (US);

Thomas H. Jozefiak, Belmont, MA (US);

Frederic Vinick, Mechanicville, NY (US);

Yibin Xiang, Acton, MA (US);

John Kane, Maynard, MA (US);

Junkai Liao, Andover, MA (US);

Inventors:

Craig Siegel, Woburn, MA (US);

Cecilia M. Bastos, South Grafton, MA (US);

David J. Harris, Lexington, MA (US);

Angeles Dios, Ashland, MA (US);

Edward Lee, Sudbury, MA (US);

Richard Silva, Needham, MA (US);

Lisa M. Cuff, Leominster, MA (US);

Mikaela Levine, Swampscott, MA (US);

Cassandra A. Celatka, Hull, MA (US);

Thomas H. Jozefiak, Belmont, MA (US);

Frederic Vinick, Mechanicville, NY (US);

Yibin Xiang, Acton, MA (US);

John Kane, Maynard, MA (US);

Junkai Liao, Andover, MA (US);

Assignee:

Genzyme Corporation, Cambridge, MA (US);

Attorney:

Hamilton, Brook, Smith & Reynolds, P.C.

Primary Examiner:

Samantha Shterengarts

Int. Cl.

CPC ...

A61K 31/397 (2006.01); A61K 31/5377 (2006.01); A61K 31/44 (2006.01); A61K 31/325 (2006.01); A61K 31/42 (2006.01); A61K 31/40 (2006.01); C07D 207/12 (2006.01); C07D 271/12 (2006.01); C07D 317/60 (2006.01); C07D 319/18 (2006.01); C07D 333/16 (2006.01); C07D 407/12 (2006.01); C07D 409/04 (2006.01); C07D 413/04 (2006.01); C07D 417/12 (2006.01); C07C 271/12 (2006.01); C07D 319/20 (2006.01); C07D 407/06 (2006.01);

U.S. Cl.

CPC ...

C07D 207/12 (2013.01); C07C 271/12 (2013.01); C07D 317/60 (2013.01); C07D 319/18 (2013.01); C07D 319/20 (2013.01); C07D 333/16 (2013.01); C07D 407/06 (2013.01); C07D 407/12 (2013.01); C07D 409/04 (2013.01); C07D 413/04 (2013.01); C07D 417/12 (2013.01);

Abstract

A compound for use in treating polycystic kidney disease is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating polycystic kidney disease in a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. Methods of treating in polycystic kidney disease in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.

Find Patent Forward Citations